Cytosorbents (NASDAQ:CTSO) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, August 6th. Analysts expect Cytosorbents to post earnings of ($0.14) per share for the quarter.
Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. The company had revenue of $5.19 million for the quarter, compared to analyst estimates of $6.03 million. Cytosorbents had a negative net margin of 83.93% and a negative return on equity of 103.90%. On average, analysts expect Cytosorbents to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of CTSO traded up $0.38 during mid-day trading on Wednesday, reaching $7.40. 1,225 shares of the stock traded hands, compared to its average volume of 98,725. The stock has a market cap of $231.23 million, a price-to-earnings ratio of -13.07 and a beta of 1.50. The firm has a fifty day moving average of $6.77. Cytosorbents has a 12-month low of $5.84 and a 12-month high of $14.95. The company has a current ratio of 3.70, a quick ratio of 3.52 and a debt-to-equity ratio of 0.62.
A number of analysts have recently issued reports on the stock. B. Riley set a $6.00 price objective on shares of Intevac and gave the company a “hold” rating in a research note on Friday, July 19th. ValuEngine lowered shares of Welbilt from a “hold” rating to a “sell” rating in a research note on Friday, July 26th. Finally, Maxim Group set a $7.00 price target on shares of Eagle Bulk Shipping and gave the stock a “buy” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $14.00.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Further Reading: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.